• Read more about Pfizer Signs Agreement to Provide the European Union with PAXLOVID™

•    New agreement to supply up to 3.4 million treatment courses to countries across Europe; this deal supplements the courses provided to 17 EU member states under existing bilateral agreements 

•    Deliveries to participating countries commencing imminently 

• Read more about Pfizer and BioNTech Advance Next-Generation COVID-19 Vaccine Strategy with Study Start of Candidate Aimed at Enhancing Breadth of T cell Responses and Duration of Protection

• Read more about Listen Now—The Antigen Season 3 Explores Maternal Immunization

The Antigen, Pfizer’s flagship podcast returns with a three-part mini-series spotlighting maternal immunization. Vaccinations for pregnant people are not new, but they have historically been left out of the vaccine narrative. As maternal immunization is advancing vaccine science and innovation, this series delves into the history, the potential benefits of boosting infant immunity, and the role of maternal antibodies in helping protect infants. We’ll also explore the challenges of maternal immunization and what the future holds.

• Read more about Pfizer and BioNTech Initiate Phase 1 Study of Single Dose mRNA-Based Combination Vaccine Candidate for Influenza and COVID-19

• Novel combination vaccination approach aims to help protect individuals against two severe respiratory viral diseases
• Candidate combines Pfizer’s quadrivalent modRNA-based influenza vaccine candidate with the companies’ Omicron-adapted bivalent COVID-19 vaccine based on BA.4/BA.5, each of which is based on BioNTech’s proprietary mRNA platform technology
• U.S.-based study to include 180 participants 18 to 64 years of age with the first participant dosed this week 

NEW YORK and MAINZ, GERMANY, November 3, 2022

• Read more about Amid COVID-19 Global Pandemic, The Pfizer Foundation Helps IRC Pursue Urgent Expansion of Health Access in Humanitarian Settings

There are more displaced people today than at any other point in history.¹

• Read more about Safety Recommendation on Janus kinase (JAK) Inhibitors Issued in the European Union

New York, October 28, 2022 — Pfizer Inc. (NYSE: PFE) announced today that the Pharmacovigilance Risk Assessment Committee (PRAC) of the European Medicines Agency (EMA) has concluded their assessment of Janus kinase (JAK) inhibitors authorized for the treatment of certain inflammatory diseases in the European Union (EU) and has provided updated recommendations for their use.

• Read more about Listen Now—Science Will Win Season 2 Takes on Breast Cancer

Science Will Win, one of Pfizer’s premiere podcasts, is back! This season we’ll explore the advancements and the challenges of cancer treatments, particularly in the breast cancer space. In this special two-part series, we’re looking at how the increasingly innovative medications used to treat cancer come to be.

• Read more about Advisory Committee on Immunization Practices Recommends Pfizer’s PREVNAR 20® for Adults Previously Vaccinated with PREVNAR 13®

NEW YORK, October 20, 2022 - Pfizer Inc. (NYSE:PFE) today announced that that the Centers for Disease Control and Prevention’s (CDC) Advisory Committee on Immunization Practices (ACIP) voted to recommend a single dose of PREVNAR 20® (Pneumococcal 20-valent Conjugate Vaccine) to help protect adults previously vaccinated with PREVNAR 13® (Pneumococcal 13-valent Conjugate Vaccine [Diphtheria CRM197 Protein]) or both PREVNAR 13® and PPSV23 against invasive disease and pneumonia caused by the 20 Streptococcus pneumoniae (pneumococcus) serotypes in PREVNAR 20®. 

• Read more about Pfizer and BioNTech Receive Positive CHMP Opinion for COMIRNATY® in Children 6 Months to less than 5 Years in the European Union

NEW YORK and MAINZ, Germany, October 19, 2022 — Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended marketing authorization (MA) for a 3-µg dose of COMIRNATY® (COVID-19 vaccine, mRNA), which is based on the wild-type spike protein of SARS-CoV-2, as a three-dose series for children ages 6 months to less than 5 years (also referred to as 6 months through 4 years of age).

• Read more about Make Kindness The Norm

Right now, we’re experiencing a greater emphasis on virtual working. All types of teams are moving to digital platforms, and in doing so are translating in-person working relationships to virtual experiences.